Infasurf

Infasurf (pronounced: in-fa-surf) is a type of pulmonary surfactant used in the treatment of Respiratory Distress Syndrome (RDS) in premature infants. It is a natural bovine lung extract containing phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins such as SP-B and SP-C.

Etymology

The term "Infasurf" is a combination of the words "infant" and "surfactant," reflecting its primary use in neonatal medicine.

Usage

Infasurf is administered intratracheally, directly into the lungs of the infant. It works by reducing the surface tension of the alveoli in the lungs, which helps to prevent the alveoli from collapsing and improves the infant's ability to breathe.

Related Terms

• Pulmonary surfactant
• Respiratory Distress Syndrome
• Alveoli
• Neonatal medicine

See Also

• Calfactant
• Poractant alfa

References

• National Institutes of Health (2021). Infasurf. MedlinePlus. Retrieved from https://medlineplus.gov/druginfo/meds/a695012.html
• Infasurf (2021). Infasurf. Retrieved from https://www.infasurf.com/

External links

• Medical encyclopedia article on Infasurf
• Wikipedia's article - Infasurf

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski